Search

Maridebart Cafraglutide

Maridebart Cafraglutide is under investigation in clinical trial NCT05669599 (Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity

Levacetylmethadol

It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. … The production of levacetylmethadol in the US has ceased as well.[L44052,T862]

Cantharidin

[A32892] Nevertheless, it gained its first FDA approval on Jul 21, 2023, under the brand name YCANTH™ by Verrica Pharmaceuticals for the treatment of molluscum contagiosum in adult and pediatric patients … [A32891, A32892] Topical cantharidin products do not necessarily demonstrate any particular better effectiveness at treating topical skin conditions like warts than other commonly available vesicant

AMG-222

Cerulenin

In fatty acid synthesis, reported to bind in equimolar ratio to b-keto-acyl-ACP synthase. In sterol synthesis, inhibits HMG-CoA synthetase activity. … It is also shown to inhibit feeding and induce dramatic weight loss in mice. It is found naturally in the Cephalosporium caerulensfungus.

Inosine

(Dorland, 28th ed) … It is an intermediate in the degradation of purines and purine nucleosides to uric acid and in pathways of purine salvage. It also occurs in the anticodon of certain transfer RNA molecules.

Mecobalamin

Glatiramer

[A248880] It was approved by the FDA in 1996, and a generic version became available in 2017. … [A248870] Along with [human interferon beta], [teriflunomide], and [dimethyl fumarate], glatiramer acetate is a first-line drug for patients with MS.

Respiratory syncytial virus vaccine, adjuvanted

[L46352] It was also later approved by Health Canada on August 4, 2023,[L47666] and the EMA in March 2025.[L52380] … It comprises lyophilized recombinant respiratory syncytial virus glycoprotein F (RSVPreF3) stabilized in pre-fusion conformation as the antigen component, which is reconstituted at the time of use with

Canagliflozin

It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type … Cardiovascular disease is the most common cause of death in these patients [A177083].